These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Daei Sorkhabi A; Mohamed Khosroshahi L; Sarkesh A; Mardi A; Aghebati-Maleki A; Aghebati-Maleki L; Baradaran B Front Immunol; 2023; 14():1113882. PubMed ID: 37020537 [TBL] [Abstract][Full Text] [Related]
23. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for? Khan AN; Asija S; Pendhari J; Purwar R Eur J Haematol; 2024 Jan; 112(1):6-18. PubMed ID: 37545253 [TBL] [Abstract][Full Text] [Related]
24. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations. Brookens SK; Posey AD Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155 [TBL] [Abstract][Full Text] [Related]
25. Altered cancer metabolism and implications for next-generation CAR T-cell therapies. Ramapriyan R; Vykunta VS; Vandecandelaere G; Richardson LGK; Sun J; Curry WT; Choi BD Pharmacol Ther; 2024 Jul; 259():108667. PubMed ID: 38763321 [TBL] [Abstract][Full Text] [Related]
26. A metabolic switch to memory CAR T cells: Implications for cancer treatment. Rostamian H; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Pawelek JM; Hadjati J; Brown CE; Mirzaei HR Cancer Lett; 2021 Mar; 500():107-118. PubMed ID: 33290868 [TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related]
28. Expanding the role of CAR T-cell therapy: From B-cell hematological malignancies to autoimmune rheumatic diseases. Shumnalieva R; Velikova T; Monov S Int J Rheum Dis; 2024 May; 27(5):e15182. PubMed ID: 38742463 [TBL] [Abstract][Full Text] [Related]
30. Universal CAR 2.0 to overcome current limitations in CAR therapy. Schlegel LS; Werbrouck C; Boettcher M; Schlegel P Front Immunol; 2024; 15():1383894. PubMed ID: 38962014 [TBL] [Abstract][Full Text] [Related]
31. Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors. Mata M; Gottschalk S Drugs; 2019 Mar; 79(4):401-415. PubMed ID: 30796733 [TBL] [Abstract][Full Text] [Related]
32. Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors. Chen J; Jiang H Crit Rev Immunol; 2021; 41(1):1-12. PubMed ID: 33822521 [TBL] [Abstract][Full Text] [Related]
33. Engineering CAR-T Cells for Improved Function Against Solid Tumors. Morgan MA; Schambach A Front Immunol; 2018; 9():2493. PubMed ID: 30420856 [TBL] [Abstract][Full Text] [Related]
36. Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors. Yuan G; Ye M; Zhang Y; Zeng X Med Oncol; 2024 Apr; 41(5):126. PubMed ID: 38652178 [TBL] [Abstract][Full Text] [Related]
37. INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults. Talleur AC; Fabrizio VA; Aplenc R; Grupp SA; Mackall C; Majzner R; Nguyen R; Rouce R; Moskop A; McNerney KO Transplant Cell Ther; 2024 Jun; 30(6):565-579. PubMed ID: 38588880 [TBL] [Abstract][Full Text] [Related]
38. Coengineering specificity, safety, and function into T cells for cancer immunotherapy. Giordano Attianese GMP; Ash S; Irving M Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063 [TBL] [Abstract][Full Text] [Related]
39. CAR T-Cell Therapy in Hematological Malignancies. Haslauer T; Greil R; Zaborsky N; Geisberger R Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701 [TBL] [Abstract][Full Text] [Related]
40. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies. El-Khazragy N; Ghozy S; Emad P; Mourad M; Razza D; Farouk YK; Mohamed NA; Ahmed MK; Youssef T; Bahnasawy YM; Elmasery S Immunotherapy; 2020 Dec; 12(18):1341-1357. PubMed ID: 33148070 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]